Development of a Functional Assessment of Chronic Illness Therapy item library and primary symptom list for the assessment of patient-reported adverse events associated with immune checkpoint modulators
暂无分享,去创建一个
D. Cella | H. Jim | A. Dicker | A. Hansen | J. Feliciano | C. Bingham | M. Janda | K. Ala-leppilampi | S. Kircher | K. Webster | N. Lynn Henry | Mary L O'Connor | Laurie E Steffen McLouth | Mary O'Connor
[1] D. Gerber,et al. Autoimmunity, Checkpoint Inhibitor Therapy and Immune-related Adverse Events: A Review. , 2020, Seminars in cancer biology.
[2] A. Oza,et al. Development of the functional assessment of cancer therapy-immune checkpoint modulator (FACT-ICM): A scale to measure quality of life in cancer patients treated with ICMs , 2019, Annals of Oncology.
[3] M. Janda,et al. An outreach telephone program for advanced melanoma supportive care: Acceptability and feasibility. , 2019, European journal of oncology nursing : the official journal of European Oncology Nursing Society.
[4] M. Ebert,et al. Management of immune related adverse events induced by immune checkpoint inhibition. , 2019, Cancer letters.
[5] L. Schapira,et al. Patient-Reported Outcomes for Cancer Patients Receiving Checkpoint Inhibitors: Opportunities for Palliative Care-A Systematic Review. , 2019, Journal of pain and symptom management.
[6] M. Levitt,et al. Adverse Effects of Immune Checkpoint Inhibitors (Programmed Death-1 Inhibitors and Cytotoxic T-Lymphocyte-Associated Protein-4 Inhibitors): Results of a Retrospective Study , 2019, Journal of clinical medicine research.
[7] L. Howie,et al. Patient reported outcomes in anti-PD-1/PD-L1 inhibitor immunotherapy registration trials: FDA analysis of data submitted and future directions , 2019, Clinical trials.
[8] Matthew J. Frigault,et al. Management of Immunotherapy-Related Toxicities, Version 1.2019. , 2019, Journal of the National Comprehensive Cancer Network : JNCCN.
[9] H. Jim,et al. Patient reported toxicities: Development and validation of patient-reported symptom measure for lung cancer patients receiving immunotherapy. , 2019, Journal of Clinical Oncology.
[10] J. Paty,et al. Patient-reported outcomes of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib (CheckMate 214): a randomised, phase 3 trial. , 2019, The Lancet. Oncology.
[11] Mark P. MacEachern,et al. Spectrum of immune checkpoint inhibitors-induced endocrinopathies in cancer patients: a scoping review of case reports , 2019, Clinical Diabetes and Endocrinology.
[12] M. Lacouture,et al. Toxic Side Effects of Targeted Therapies and Immunotherapies Affecting the Skin, Oral Mucosa, Hair, and Nails , 2018, American Journal of Clinical Dermatology.
[13] Claire Wang,et al. Management of Immune Checkpoint Inhibitor Toxicities: A Review and Clinical Guideline for Emergency Physicians. , 2018, The Journal of emergency medicine.
[14] G. Myers. Immune-related adverse events of immune checkpoint inhibitors: a brief review. , 2018, Current oncology.
[15] A. Gabrielli,et al. Musculoskeletal and Rheumatic Diseases Induced by Immune Checkpoint Inhibitors: A Review of the Literature , 2018, Current drug safety.
[16] A. Palumbo,et al. Impact of elotuzumab treatment on pain and health-related quality of life in patients with relapsed or refractory multiple myeloma: results from the ELOQUENT-2 study , 2018, Annals of Hematology.
[17] A. Tai,et al. Immune Checkpoint Inhibitor-Associated Colitis and Hepatitis , 2018, Clinical and Translational Gastroenterology.
[18] Laura C. Cappelli,et al. Rheumatic immune-related adverse events from cancer immunotherapy , 2018, Nature Reviews Rheumatology.
[19] M. Hara,et al. Use of Immune Checkpoint Inhibitors in the Treatment of Patients With Cancer and Preexisting Autoimmune Disease , 2018, Annals of Internal Medicine.
[20] M. Atkins,et al. The Current Understanding of the Endocrine Effects From Immune Checkpoint Inhibitors and Recommendations for Management , 2018, JNCI cancer spectrum.
[21] V. Sibaud. Dermatologic Reactions to Immune Checkpoint Inhibitors , 2018, American Journal of Clinical Dermatology.
[22] D. Cella,et al. Cancer symptom response as an oncology clinical trial end point , 2018, Expert review of quality of life in cancer care.
[23] J. Szustakowski,et al. Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden , 2018, The New England journal of medicine.
[24] L. Kottschade. Incidence and Management of Immune-Related Adverse Events in Patients Undergoing Treatment with Immune Checkpoint Inhibitors , 2018, Current Oncology Reports.
[25] L. Shen,et al. Management of gastrointestinal adverse events induced by immune-checkpoint inhibitors , 2018, Chronic diseases and translational medicine.
[26] M. Suarez‐Almazor,et al. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] R. Motzer,et al. Quality of Life Outcomes for Cabozantinib Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma: METEOR Phase III Randomized Trial. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[28] R. Sullivan,et al. Keeping Expectations in Check With Immune Checkpoint Inhibitors. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[29] G. De Velasco,et al. Analysis of response rate with ANTI PD1/PD-L1 monoclonal antibodies in advanced solid tumors: a meta-analysis of randomized clinical trials , 2018, Oncotarget.
[30] Matthew D. Hellmann,et al. Immune‐Related Adverse Events Associated with Immune Checkpoint Blockade , 2018, The New England journal of medicine.
[31] M. Suarez‐Almazor,et al. Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group , 2017, Journal of Immunotherapy for Cancer.
[32] V. Anagnostou,et al. Immuno-oncology Trial Endpoints: Capturing Clinically Meaningful Activity , 2017, Clinical Cancer Research.
[33] N. Girard,et al. Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients , 2017, European Respiratory Journal.
[34] K. Kerr,et al. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.
[35] C. L. Ventola,et al. Cancer Immunotherapy, Part 2: Efficacy, Safety, and Other Clinical Considerations. , 2017, P & T : a peer-reviewed journal for formulary management.
[36] M. Suarez‐Almazor,et al. Review: Immune‐Related Adverse Events With Use of Checkpoint Inhibitors for Immunotherapy of Cancer , 2017, Arthritis & rheumatology.
[37] H. McLeod,et al. American Society of Clinical Oncology Value Framework: Importance of Accurate Toxicity Data. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[38] E. Basch,et al. Exploring differences in adverse symptom event grading thresholds between clinicians and patients in the clinical trial setting , 2017, Journal of Cancer Research and Clinical Oncology.
[39] Y. Shentu,et al. Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. , 2016, The New England journal of medicine.
[40] Ami A. Shah,et al. Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumab , 2016, Annals of the rheumatic diseases.
[41] J. Soria,et al. Immune-related adverse events with immune checkpoint blockade: a comprehensive review. , 2016, European journal of cancer.
[42] K. Lohr,et al. Patient-Reported Outcomes in Performance Measurement , 2015 .
[43] A. Razak,et al. A systematic review of immune-related adverse event reporting in clinical trials of immune checkpoint inhibitors. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.
[44] D. Cella,et al. Re-personalizing precision medicine: is there a role for patient-reported outcomes? , 2015 .
[45] B. Vogelstein,et al. PD-1 blockade in tumors with mismatch repair deficiency. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[46] Amy P Abernethy,et al. Development of the National Cancer Institute's patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE). , 2014, Journal of the National Cancer Institute.
[47] F. Hasson,et al. The Delphi Technique in Nursing and Health Research , 2011 .
[48] Daniel J Buysse,et al. The Patient-Reported Outcomes Measurement Information System (PROMIS) developed and tested its first wave of adult self-reported health outcome item banks: 2005-2008. , 2010, Journal of clinical epidemiology.
[49] Alexia Iasonos,et al. Adverse symptom event reporting by patients vs clinicians: relationships with clinical outcomes. , 2009, Journal of the National Cancer Institute.
[50] David Artz,et al. Long-term toxicity monitoring via electronic patient-reported outcomes in patients receiving chemotherapy. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[51] U. S. Department of Health and Human Services FDA Cen Research,et al. Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims: draft guidance , 2006, Health and quality of life outcomes.
[52] David Cella,et al. A Comprehensive Method for the Translation and Cross-Cultural Validation of Health Status Questionnaires , 2005, Evaluation & the health professions.
[53] David Cella,et al. The Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System: properties, applications, and interpretation , 2003, Health and quality of life outcomes.
[54] J. Crisp,et al. The Delphi method? , 1997, Nursing research.
[55] D. Cella,et al. Multilingual translation of the Functional Assessment of Cancer Therapy (FACT) quality of life measurement system , 1996, Quality of Life Research.
[56] D. Osoba,et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. , 1993, Journal of the National Cancer Institute.
[57] C. Robert,et al. Haematological immune-related adverse events induced by anti-PD-1 or anti-PD-L1 immunotherapy: a descriptive observational study. , 2019, The Lancet. Haematology.